1. Outcomes of pirtobrutinib for relapsed/refractory mantle cell lymphoma in compassionate use program in Europe.
- Author
-
Aydilek, Enver, Wulf, Gerald, Schwarz, Friedrich, Bacher, Ulrike, Rummel, Mathias, Stiefel, Olga, Kerkhoff, Andrea, Maulhardt, Markus, Melchardt, Thomas, Pabst, Thomas, Lenz, Georg, and Shumilov, Evgenii
- Subjects
MANTLE cell lymphoma ,OVERALL survival ,PROGRESSION-free survival - Abstract
Background: Mantle cell lymphoma (MCL) is a type of B‐cell lymphoma that is currently incurable. Pirtobrutinib shows promising response rates in heavily pretreated MCL patients according to the approval study, but the real‐world data are scarce. Methods: In this study, we retrospectively analyzed the efficacy and safety profile of pirtobrutinib in 10 relapsed/refractory MCL patients from compassionate use program (CUP). Results: On average, the patients underwent three lines of systemic therapy prior to pirtobrutinib and were predominantly BTKi exposed (9/10). The best overall response rate (BORR) was 67%. In a median follow‐up of 8.6 months, the mean duration of response (DOR), progression‐free survival (PFS), and overall survival (OS) were not reached. No new safety signals were documented. Conclusions: In summary, pirtobrutinib represented a safe and effective treatment option in a small real‐world population. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF